Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population

Clinics

Volumn 68, Issue 1, 2013, Pages 5-9

  Pagliarini e Silva, Sarah ^a,b   Santos, Bruna Cunha ^a   Pereira, Elizangela Mendes de Figueiredo ^a   Ferreira, Mari Ellen ^b   Baraldi, Elaine Cristina ^c   Sell, Ana Maria ^a   Visentainer, Jeane Eliete Laguila ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b Hospital Universitario de Maringa   (Brazil)

^c Hospital do Câncer de Londrina   (Brazil)

Author keywords

Haplotype; JAK2 human; Myeloproliferative disorders

Indexed keywords

BCR ABL PROTEIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

AGED; ARTICLE; BRAZIL; CHI SQUARE DISTRIBUTION; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENETICS; HAPLOTYPE; HUMAN; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX RATIO; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; BRAZIL; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; FEMALE; FUSION PROTEINS, BCR-ABL; GENE FREQUENCY; HAPLOTYPES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84874138259     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(01)OA02     Document Type: Article

References (21)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Ed.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer: 2008. 439p.
2. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162-8.
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005;365(9464):1054-61.
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg J. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C. et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycithemia vera. Nature. 2005;434(7037):1144-8.
6. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19(49):5662-79.
7. Barcelos MM, Santos-Silva MC. Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2011;33(4):290-6.
8. Bellané-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006; 108(1):346-52.
9. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M. Increasead risk of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24577 first-degree relatives of 11039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199-04.
10. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111(5):2785-9.
11. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-9.
12. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2 V617F-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-9.
13. Monte-Mór BCR, Costa FF. A mutação JAK2 V617F e as síndromes mieloproliferativas. Rev Bras Hematol Hemoter. 2008;30(3):241-8.
14. Monte-Mór BCR, Cunha AF, Pagnano KBB, Saad ST, Lorand-Metze I, Costa FF. JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia. Genet Mol Biol. 2007;30(2):336-8.
15. Trifa AP, Cucuianu A, Popp RA. Development of a reliable PCR-RFLP assay for investigation of the JAK2 rs10974944 SNP, which might predispose to the acquisition of somatic mutation JAK2 V617F. Acta Haematol. 2010;123(2):84-7.
16. Trifa AP, Cucuianu A, Ljubomir P, Urian L, Militaru MS, Dima D, et al. The G allele of the JAK2 rs10974944 SNP, part of the JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann Hematol. 2010;89(10):979-83.
17. Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia. 2009;23(10):1924-6.
18. Goldin LR, Bjorkholm M, Kristinsson SY, Samuelsson J, Landgren O. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome Medicine. 2009;1(5):55-5.
19. Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC Med Genet. 2012;17:13-6.
20. Tian ZQ, Zhu P, Liu HX, Chen Y, Wang F, Zhang Y, Teng W, et al. Relationship between V617F mutation and 46/1 haplotype in JAK2 gene in patients with chronic myeloproliferative diseases and frequencies of 46/1 haplotype in different Chinese nationalities. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(2):362-7.
21. Machado-Neto JA, Traina F, Lazarini M, Campos PM, Pagnano KB, Lorand-Metze I, Costa FF, Saad ST. Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. Clinics. 2011;66(5):793-9.